Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Direct-to-Consumer Marketing of Prescription Pharmaceuticals in Europe' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Daiichi Sankyo Company, Ltd - Financial and Strategic Analysis Review |
April 2009 | £76 | 50 % |
|
Purdue Pharma L.P. - Strategic Analysis Review |
March 2009 | £76 | 48.5 % |
|
Mission Pharmacal Company - Strategic Analysis Review |
June 2009 | £76 | 36.5 % |
|
Pharmaceutical Regulatory Affairs in the EU and US |
December 2006 | £1095 | 23.5 % |
|
Pharmaceutical Distribution in the US Current and Future Perspectives |
July 2009 | £1495 | 21 % |
|
Patient Empowerment Empowered Patients Can Change Healthcare Outcomes And Impact The Pharmaceutical Industry |
July 2007 | £3000 | 20.3 % |
|
Reporting Adverse Events |
September 2006 | £75 | 15.4 % |
|
Online Pharmaceutical Industry, 2006-2011, The |
July 2006 | £1499 | 15.05 % |
|
Pricing & Reimbursement in Europe Can the drive for cost effectiveness overcome cost containment? |
October 2006 | £6000 | 12.95 % |
|
McKesson Corporation Medical Equipment Company Share Analysis |
September 2008 | £610 | 11.9 % |
|
The Pharmaceutical Industry 2008 Current and Future Trends and Strategic Issues Shaping Pharma |
March 2008 | £3010 | 11.2 % |
|
Commercial Insight: Cardiovascular market overview Raft of patent expires threaten blockbusters |
October 2007 | £7600 | 10.85 % |
|
World Generic Market Report 2009 |
January 2009 | £595 | 10.15 % |
|
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth |
October 2008 | £8000 | 8.75 % |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £7600 | 8.75 % |
